Cargando…

Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease

INTRODUCTION: Donanemab is an amyloid‐targeting therapy that specifically targets brain amyloid plaques. The objective of these analyses was to characterize the relationship of donanemab exposure with plasma biomarkers and clinical efficacy through modeling. METHODS: Data for the analyses were from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gueorguieva, Ivelina, Willis, Brian A., Chua, Laiyi, Chow, Kay, Ernest, C. Steven, Wang, Jian, Shcherbinin, Sergey, Sims, John R., Chigutsa, Emmanuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301702/ https://www.ncbi.nlm.nih.gov/pubmed/37388759 http://dx.doi.org/10.1002/trc2.12404

Ejemplares similares

Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease
por: Lowe, Stephen Loucian, et al.
Publicado: (2021)

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial
por: Shcherbinin, Sergey, et al.
Publicado: (2022)

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial
por: Pontecorvo, Michael J., et al.
Publicado: (2022)

Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials
por: Rashad, Areeba, et al.
Publicado: (2022)

TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease
por: Salloway, Stephen, et al.
Publicado: (2023)

Effect of Lecanemab and Donanemab in Early Alzheimer’s Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective
por: Volloch, Vladimir, et al.
Publicado: (2023)

Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings
por: Wessels, Alette M., et al.
Publicado: (2023)

Donanemab detects a minor fraction of amyloid-β plaques in post-mortem brain tissue of patients with Alzheimer’s disease and Down syndrome
por: Bouter, Yvonne, et al.
Publicado: (2022)

Dose/Exposure‐Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis
por: Zhang, Xin, et al.
Publicado: (2017)

Exposure–Response Analysis of Necitumumab Efficacy in Squamous Non‐Small Cell Lung Cancer Patients
por: Chigutsa, E, et al.
Publicado: (2017)

Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer’s Disease Dementia
por: Lo, Albert C., et al.
Publicado: (2021)

PK/PD modeling links accelerated resolution of COVID‐19‐related clinical symptoms to SARS‐CoV‐2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together
por: Ernest, C. Steven, et al.
Publicado: (2022)

Population pharmacokinetic and exposure–efficacy analysis of ixekizumab in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)
por: Jackson, Kimberley, et al.
Publicado: (2021)

Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials
por: Wessels, Alette M., et al.
Publicado: (2020)

Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia
por: Svaldi, Diana Otero, et al.
Publicado: (2022)

Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
por: Chua, Laiyi, et al.
Publicado: (2023)

Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer’s Disease: A Phase I Clinical Trial
por: Willis, Brian A., et al.
Publicado: (2023)

Population Pharmacokinetics of Necitumumab in Cancer Patients
por: Long, Amanda, et al.
Publicado: (2016)

Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease
por: Shcherbinin, Sergey, et al.
Publicado: (2023)

Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease
por: Zimmer, Jennifer A., et al.
Publicado: (2021)

Efficacy and Safety of Ultra-Rapid Lispro in Younger and Older Patients with Type 2 Diabetes: Randomized Double-Blind PRONTO-T2D Study
por: Zhang, Qianyi, et al.
Publicado: (2022)

Once Weekly Basal Insulin Fc (BIF) is Safe and Efficacious in Patients with Type 2 Diabetes Mellitus (T2DM) Previously Treated With Basal Insulin
por: Frias, Juan Pablo, et al.
Publicado: (2021)

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Dose Rationale of Nasal Glucagon in Japanese Pediatric Patients with Diabetes Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation
por: Nasu, Risa, et al.
Publicado: (2023)

A deep ensemble model to predict miRNA-disease association
por: Fu, Laiyi, et al.
Publicado: (2017)

Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID‐19 Infection
por: Chigutsa, Emmanuel, et al.
Publicado: (2021)

Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer
por: Gueorguieva, Ivelina, et al.
Publicado: (2016)

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
por: Harding, James J., et al.
Publicado: (2021)

Exposure‐safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate
por: Gidal, B. E., et al.
Publicado: (2018)

Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma
por: Chia, Yen Lin, et al.
Publicado: (2019)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti‐SARS‐CoV‐2 Monoclonal Antibodies to Advance Bamlanivimab Into a First‐in‐Human Clinical Trial
por: Chigutsa, Emmanuel, et al.
Publicado: (2021)

Searching the Dark Genome for Alzheimer’s Disease Risk Variants
por: Raybould, Rachel, et al.
Publicado: (2021)

Structure‒tissue exposure/selectivity relationship (STR) correlates with clinical efficacy/safety
por: Gao, Wei, et al.
Publicado: (2022)

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma
por: Wick, Antje, et al.
Publicado: (2020)

Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer’s disease
por: Biel, Davina, et al.
Publicado: (2022)

Relationship of aluminum to Alzheimer's disease.
por: Perl, D P
Publicado: (1985)

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer
por: Nadal, Ernest, et al.
Publicado: (2023)

A multicentre longitudinal study of flortaucipir ((18)F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia
por: Pontecorvo, Michael J, et al.
Publicado: (2019)

The pyrazinamide susceptibility breakpoint above which combination therapy fails
por: Gumbo, Tawanda, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qm68vjbb60bl3tgu6t0cnsson9